NEWSROOM
Stay current with MiRXES
Insights
Welcome to our knowledge base of insights on the frontiers of the biotech industry.
Congratulations to Associate Professor Too Heng-Phon from the Department of Biochemistry and NUS Centre for Cancer Research at NUS Medicine, who has been conferred the President’s Technology Award 2021
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.
As the world’s first molecular blood test for detecting gastric cancer, GASTROClear could play a pivotal role in stopping the deadly disease in its earliest stages.
As Co-founder and CEO of MiRXES, Dr Zhou Lihan has led the company in its journey from humble start-up to a global leader in miRNA-powered diagnostics.
For Dr. Cheng He, Vice President for Research and Development at MiRXES, research is all about innovating for impact and improving people’s health in the process.
As Vice President for Manufacturing and Regulatory Affairs at MiRXES, Jeremiah Decosta harnesses smart technologies to accelerate processes in the plants while ensuring quality diagnostics.
PI Rxes, a disease detective from MiRXES that harnesses the power of miRNA to save and improve lives.
Now a trusted name in biotechnology manufacturing, MiRXES is hoping to boost its capabilities by tapping upon local talent and the defining technologies of Industry 4.0.
From regulating genes to aiding disease diagnosis, microRNAs’ outsized impact certainly belies their tiny proportions.
Discover how MiRXES and its partners are developing early detection tests to fight the world’s leading cause of death: heart disease.
Amidst the highs and lows of 2020, MiRXES managed to rise to the occasion and make our name on a global stage.
Armed with a wealth of experience from the pandemic, MiRXES is now set to return to its roots and focus on producing best-in-class multi-cancer early diagnostics.
Compared to other commercial microRNA profiling platforms, MiRXES’s ID3EAL qPCR platform stands out when used to discover and validate blood-based miRNA biomarkers.
MiRXES is on the lookout for talents who can contribute to its mission against diseases like cancer through leading-edge diagnostic tools.
Founded with a focus on microRNA discoveries and diagnostics, MiRXES is now looking to solidify its manufacturing and delivery capabilities and help Singapore elevate its competitiveness on the global stage.
SOCIAL MEDIA
- Genomics
- Clinical Sequencing
- Research Sequencing
- Cancer Screening
- GASTROClear for Patients
- GASTROClear for Medical Professionals
- LUNGClear
- Cancer Treatment Selection
- APEX Tissue Panel for Medical Professionals
- Infectious Diseases
- Fortitude 2.1
- Fortitude 3.0
- Fortitude Syndromic Panel
- CoVClear Mutation Panel
- Swab & Saliva Collection
- RNA Extraction Kit & Instruments